PALISADE BIO, INC. — Director's Dealing 2021

Apr 29, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PALISADE BIO, INC. (PALI)
CIK: 0001357459
Period of Report: 2021-04-27

Reporting Person: Dawson Michael John (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-27	Stock Option (Right to Buy)	$27.59	A	5438	Acquired	2027-02-10	Common Stock (5438)	Direct
2021-04-27	Stock Option (Right to Buy)	$53.33	A	20391	Acquired	2028-07-24	Common Stock (20391)	Direct
2021-04-27	Stock Option (Right to Buy)	$41.20	A	5084	Acquired	2029-03-22	Common Stock (5084)	Direct
2021-04-27	Stock Option (Right to Buy)	$41.20	A	1962	Acquired	2029-03-22	Common Stock (1962)	Direct
2021-04-27	Stock Option (Right to Buy)	$26.85	A	2800	Acquired	2030-02-19	Common Stock (2800)	Direct

Footnotes

F1: The stock option vested in four equal quarterly installments from the vesting commencement date.

F2: Received in exchange for a stock option to acquire 200,000 shares of common stock of Leading BioSciences, Inc. ("LBS") for $0.75 per share, pursuant to the Agreement and Plan of Merger, dated December 16, 2020, among Seneca Biopharma Inc., Townsgate Acquisition Sub 1, Inc. and LBS (the "Merger"). Per the terms of the Merger, each share of LBS's common stock was converted into the right to receive 0.02719 shares of Seneca's common stock. In the Merger, the name of the Issuer was changed from Seneca Biopharma, Inc. to Palisade Bio, Inc.

F3: The stock option vests according to the following schedule: 17% of the shares underlying the option vests on grant date and the remaining 83% vests in 10 quarterly installments thereafter beginning on September 30, 2018.

F4: Received in the Merger in exchange for a stock option to acquire 750,000 shares of LBS common stock for $1.45 per share.

F5: The stock option vests according to the following schedule: 33% of the shares underlying the option vests on grant date and the remaining 67% vests in eight equal quarterly installments thereafter beginning on March 31, 2019.

F6: Received in the Merger in exchange for a stock option to acquire 187,000 shares of LBS common stock for $1.12 per share.

F7: Received in the Merger in exchange for a stock option to acquire 72,200 shares of LBS common stock for $1.12 per share.

F8: Received in the Merger in exchange for a stock option to acquire 103,000 shares of LBS common stock for $0.73 per share.